Clinical Research Directory

Inclusion Criteria: * Adults aged 18 years or older. History of ischemic or hemorrhagic stroke confirmed clinically and/or by neuroimaging when available. Post-stroke shoulder pain on the hemiplegic side with VAS pain intensity \>=4/10 during rest, passive movement or functional use. Spasticity of target shoulder-girdle muscles with MAS score \>=2. Stable medical condition allowing outpatient or inpatient interventional procedure. Ability to provide written informed consent; if the patient has a communication impairment, consent will follow institutional ethics-approved procedures involving legally authorized representatives when appropriate. Expected ability to attend scheduled follow-up visits through 6 months Exclusion Criteria: * Previous radiofrequency treatment or phenol neurolysis to the affected shoulder within the previous 6 months. Botulinum toxin injection to the target shoulder muscles within the previous 3-6 months. Shoulder fracture, dislocation or rotator cuff tear requiring surgery. Active infection at the injection site. Known allergy or contraindication to phenol, local anesthetic, antiseptic solution or other procedure-related medication. Coagulopathy, platelet disorder or anticoagulant/antiplatelet treatment that cannot be safely managed according to local anesthesia/interventional-pain policy. Severe uncontrolled medical illness, unstable cardiopulmonary disease, uncontrolled diabetes with active infection risk, or any condition judged by investigators to increase procedural risk. Severe cognitive, behavioral, or communication impairment preventing reliable pain/outcome assessment unless a validated caregiver-assisted assessment approach is approved by the ethics committee. Pregnancy or lactation, when applicable, because of procedural medication exposure and safety monitoring requirements. Concurrent participation in another interventional trial that may affect shoulder pain, tone or function.